c-MET (D1228Y)
Sign in to save this workspaceMET · Variant type: point · HGVS: p.D1228Y
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 98.0% | 2.0% | 88.97 |
| 2 | Tivozanib | 87.8% | 12.2% | 92.42 |
| 3 | Pacritinib | 80.0% | 20.0% | 88.64 |
| 4 | Neratinib | 79.6% | 20.4% | 93.18 |
| 5 | Repotrectinib | 78.7% | 21.3% | 84.21 |
| 6 | Defactinib | 71.6% | 28.4% | 92.68 |
| 7 | Selpercatinib | 53.4% | 46.6% | 96.72 |
| 8 | Canertinib | 49.2% | 50.8% | 96.49 |
| 9 | Sunitinib | 47.9% | 52.1% | 91.73 |
| 10 | Tepotinib | 46.0% | 54.0% | 99.75 |
| 11 | Fedratinib | 38.5% | 61.5% | 96.21 |
| 12 | Abemaciclib | 37.7% | 62.3% | 91.48 |
| 13 | Capmatinib | 24.6% | 75.4% | 99.75 |
| 14 | Entrectinib | 22.0% | 78.0% | 93.69 |
| 15 | Vandetanib | 17.4% | 82.6% | 95.74 |
| 16 | Pexidartinib | 17.3% | 82.7% | 99.49 |
| 17 | Erlotinib | 15.4% | 84.6% | 99.75 |
| 18 | Avapritinib | 14.9% | 85.1% | 97.73 |
| 19 | Pralsetinib | 13.0% | 87.0% | 93.43 |
| 20 | Darovasertib | 12.3% | 87.7% | 96.99 |
| 21 | Capivasertib | 11.9% | 88.1% | 96.48 |
| 22 | Pirtobrutinib | 9.8% | 90.2% | 99.49 |
| 23 | Lazertinib | 8.5% | 91.5% | 97.47 |
| 24 | Inavolisib | 8.0% | 92.0% | 100.00 |
| 25 | Asciminib | 7.6% | 92.4% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 98.0% | — | — |
| Tivozanib | 87.8% | — | — |
| Pacritinib | 80.0% | — | — |
| Neratinib | 79.6% | — | — |
| Repotrectinib | 78.7% | — | — |
| Defactinib | 71.6% | — | — |
| Selpercatinib | 53.4% | — | — |
| Canertinib | 49.2% | — | — |
| Sunitinib | 47.9% | — | — |
| Tepotinib | 46.0% | — | — |
| Fedratinib | 38.5% | — | — |
| Abemaciclib | 37.7% | — | — |
| Capmatinib | 24.6% | — | — |
| Entrectinib | 22.0% | — | — |
| Vandetanib | 17.4% | — | — |
| Pexidartinib | 17.3% | — | — |
| Erlotinib | 15.4% | — | — |
| Avapritinib | 14.9% | — | — |
| Pralsetinib | 13.0% | — | — |
| Darovasertib | 12.3% | — | — |
| Capivasertib | 11.9% | — | — |
| Pirtobrutinib | 9.8% | — | — |
| Lazertinib | 8.5% | — | — |
| Inavolisib | 8.0% | — | — |
| Asciminib | 7.6% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms